Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
Want to see KZIA full AI Analyst Report?
KZIA Stock Chart & Stats
$6.44
-$0.01(-0.57%)
At close: 4:00 PM EST
$6.44
-$0.01(-0.57%)
Day’s Range― - ―
52-Week Range$4.86 - $17.40
Previous CloseN/A
Volume31.49K
Average Volume (3M)209.48K
Market Cap
$130.36M
Enterprise Value-$40.48M
Total Cash (Recent Filing)$69.39M
Total Debt (Recent Filing)$98.71K
Price to Earnings (P/E)―
Beta2.18
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,335,992
10 Day Avg. Volume60,839
30 Day Avg. Volume209,481
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.26
Price to Sales (P/S)248.45
P/FCF Ratio-0.79
Enterprise Value/Market Cap-0.31
Enterprise Value/Revenue-2.05K
Enterprise Value/Gross Profit-2.05K
Enterprise Value/Ebitda2.23
Forecast
1Y Price Target
$24.33Price Target Upside277.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Cash RunwayA multi-year cash runway with no debt materially reduces near-term financing pressure, enabling Kazia to advance multiple clinical programs in parallel, fund pivotal development steps and engage strategically with partners without immediate dilution risk—a durable enabler for clinical-stage biotech execution.
Expanded, Differentiated PipelineAcquiring an exclusive, first-in-class SETDB1 platform and adding preclinical assets broadens Kazia's modality mix beyond paxalisib, improving de-risking via portfolio diversification and enhancing partnering value. Building IND-ready programs in ~18 months supports a sustained clinical development pathway.
Strengthened Executive TalentHiring a CFO with extensive biotech capital markets and transaction experience increases the company's ability to structure licensing/M&A and financing on favorable terms. Improved financial leadership and aligned incentives support durable strategic execution through pivotal clinical inflection points.
Bears Say
Minimal And Volatile RevenueA vanishing and volatile revenue base signals the company remains far from commercial self-sufficiency; ongoing operating spend is not covered by product sales. This structural revenue weakness makes long-term sustainability contingent on successful clinical readouts or continued external funding.
Persistent Cash BurnSustained negative operating and free cash flow indicates the company must repeatedly access capital markets or partners to fund development. Even with recent raises, persistent burn creates execution risk if financing windows narrow or terms deteriorate, affecting long-term program continuity.
Negative Equity And Shrinking AssetsNegative shareholder equity and a materially reduced asset base reflect accumulated losses and capital erosion, which constrain financial flexibility and could complicate partner negotiations or borrowing. These balance-sheet weaknesses are a durable vulnerability until profitability or sustained funding reverses the trend.
Kazia Therapeutics News
KZIA FAQ
What was Kazia Therapeutics Limited’s price range in the past 12 months?
Kazia Therapeutics Limited lowest stock price was $4.86 and its highest was $17.40 in the past 12 months.
What is Kazia Therapeutics Limited’s market cap?
Kazia Therapeutics Limited’s market cap is $130.36M.
When is Kazia Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kazia Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Kazia Therapeutics Limited overvalued?
According to Wall Street analysts Kazia Therapeutics Limited’s price is currently Undervalued.
Does Kazia Therapeutics Limited pay dividends?
Kazia Therapeutics Limited does not currently pay dividends.
What is Kazia Therapeutics Limited’s EPS estimate?
Kazia Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kazia Therapeutics Limited have?
Kazia Therapeutics Limited has 11,335,992 shares outstanding.
What happened to Kazia Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kazia Therapeutics Limited?
Currently, no hedge funds are holding shares in KZIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kazia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.33 (277.85% Upside)
$24.33 (277.85% Upside)
Blogger Sentiment
Neutral
KZIA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 36.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-73.42%
12-Months-Change
Fundamentals
Return on Equity
-116.86%
Trailing 12-Months
Asset Growth
327.60%
Trailing 12-Months
Company Description
Kazia Therapeutics Limited
Kazia Therapeutics Limited is a biotechnology firm primarily dedicated to creating pharmaceutical treatments for cancer. Its leading therapeutic asset is Paxalisib, a distinctive small molecule that can penetrate the brain and works by inhibiting the PI3K/Akt/mTor pathway, showing promise as a potential remedy for glioblastoma. The company is also progressing with EVT801, an experimental medication being investigated for its efficacy against various cancer types. Incorporated in 1994, the entity operated under the name Novogen Limited until its rebranding to Kazia Therapeutics Limited in November 2017. The company's main operations are based in Sydney, Australia.
KZIA Stock 12 Month Forecast
Average Price Target
$24.33
▲(277.85% Upside)
Technical Analysis
Phio Pharmaceuticals
―
XTL Biopharmaceuticals Sponsored ADR
―
Marker Therapeutics
―
―
TransCode Therapeutics
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
9.82% Other Institutional Investors
90.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---